Bruce Booth - 28 Jun 2022 Form 4 Insider Report for Magenta Therapeutics, Inc. (DNTH)

Reporting relationship: Director
Issuer ticker: DNTH
Reported as of: 28 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Jun 2022, 19:28:14 UTC
Prior SEC filing: 16 Jun 2022
Next SEC filing: 01 Nov 2022
Source filing: View source filing
Reporting owner signature: /s/ Ommer Chohan, Attorney-in-Fact for Bruce Booth

Key filing fact

Bruce Booth filed Form 4 for Magenta Therapeutics, Inc. (DNTH) on 30 Jun 2022.

Key facts

This page summarizes Bruce Booth's Form 4 filing for Magenta Therapeutics, Inc. (DNTH).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 30 Jun 2022, 19:28.

Change

Previous filing in this sequence was filed on 16 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MGTA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +20,000
Change %
Price: $0.000000
Shares after: 20,000
Date: 28 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $1.21
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option shall vest and become exercisable in full upon the earlier to occur of (a) June 28, 2023 or (b) the next annual meeting of the Issuer's stockholders.

Footnote F2

This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.